Search results for " hematologic malignancies"

showing 1 items of 1 documents

Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies

2011

The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experiment…

lcsh:Internal medicineCancer Researchbusiness.industryT cellmedicine.medical_treatmentCellImmunotherapylcsh:Other systems of medicineVc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - CytotoxicityVc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - Cytotoxicitylcsh:RZ201-999Vg9Vd2 T cells immunotherapy hematologic malignanciesIn vitroCytolysismedicine.anatomical_structureDownregulation and upregulationOncologyIn vivoImmunologymedicineCytotoxicitybusinesslcsh:RC31-1245Oncology Reviews
researchProduct